Hosted by swissnex San Francisco, RETHINK fellows and a select international group of scientists presented the latest advances of AI in drug design. The audience engaged in a lively discussion about the applicability of these new technologies. Will AI deliver new drugs faster? Will AI help develop personalized medicines? What are the limitations of AI in healthcare? These and many more questions were actively addressed. As the first of its grand challenges, the RETHINK initiative at ETH Zurich strives to explore the possibilities and limitations of AI in drug discovery .